Martin Mackay - Novo Nordisk Independent Director
| NVO Stock | USD 123.05 1.54 1.24% |
Director
Dr. Martin Mackay, Ph.D. was Independent Director of NOVO NORDISK AS since March 22, 2018. He is Chairman of the Research Development Committee. He cofounded Rallybio LLC, US, in January 2018 and serves as chair of the board and in an executive leadership role overseeing all research and nonresearch functions. He is Senior Advisor to New Leaf Venture Partners, LLC, US and Member of the board of Charles River Laboratories International, Inc., US. He holds DoctoratePhD from University of Edinburgh, UK, BSc in Microbiology from HeriotWatt University, Edinburgh, UK . since 2018.
| Age | 64 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Address | Novo Alle 1, Bagsvaerd, Denmark, 2880 |
| Phone | 45 44 44 88 88 |
| Web | https://www.novonordisk.com |
Martin Mackay Latest Insider Activity
Tracking and analyzing the buying and selling activities of Martin Mackay against Novo Nordisk stock is an integral part of due diligence when investing in Novo Nordisk. Martin Mackay insider activity provides valuable insight into whether Novo Nordisk is net buyers or sellers over its current business cycle. Note, Novo Nordisk insiders must abide by specific rules, including filing SEC forms every time they buy or sell Novo Nordisk'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Martin MacKay over a year ago Acquisition by Martin MacKay of 214000 shares of Rallybio Corp subject to Rule 16b-3 |
Novo Nordisk Management Efficiency
The company has Return on Asset of 0.2524 % which means that on every $100 spent on assets, it made $0.2524 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.9987 %, implying that it generated $0.9987 on every 100 dollars invested. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Novo Nordisk's Return On Tangible Assets are very stable compared to the past year. As of the 7th of May 2024, Return On Capital Employed is likely to grow to 0.74, while Return On Assets are likely to drop 0.14. At this time, Novo Nordisk's Return On Tangible Assets are very stable compared to the past year. As of the 7th of May 2024, Intangibles To Total Assets is likely to grow to 0.20, while Non Currrent Assets Other are likely to drop about 1.4 B.Similar Executives
Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Novo Nordisk is traded on New York Stock Exchange in the United States. Novo Nordisk AS (NVO) is traded on New York Stock Exchange in USA. It is located in Novo Alle 1, Bagsvaerd, Denmark, 2880 and employs 66,015 people. Novo Nordisk is listed under Pharmaceuticals category by Fama And French industry classification.Management Performance
Novo Nordisk AS Leadership Team
Elected by the shareholders, the Novo Nordisk's board of directors comprises two types of representatives: Novo Nordisk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novo. The board's role is to monitor Novo Nordisk's management team and ensure that shareholders' interests are well served. Novo Nordisk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novo Nordisk's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Doug Langa, Senior Vice President Head of North America Operations and Presidentident of Novo Nordisk Inc. | ||
| Kasim Kutay, Director | ||
| Sylvie Gregoire, Independent Director | ||
| Mette Jensen, Director, Employee Representative | ||
| Douglas Langa, Executive Vice President - North America Operations | ||
| Thomas Rantzau, Director, Employee Representative | ||
| Lars Jorgensen, CEO President | ||
| Daniel Bohsen, CVP Relations | ||
| Henrik Poulsen, Director | ||
| Karsten Knudsen, Chief Financial Officer, Executive Vice President | ||
| Lars Joergensen, President, Chief Executive Officer | ||
| Helge Lund, Independent Chairman of the Board | ||
| Martin Lange, Executive Vice President - Development | ||
| Maziar Doustdar, Executive Vice President - International Operations | ||
| Brian Daniels, Independent Director | ||
| Martin Mackay, Independent Director | ||
| Jeppe Christiansen, Vice Chairman of the Board | ||
| Anne Kverneland, Director, Employee Representative | ||
| Tania Sabroe, Executive Board | ||
| Liz Hewitt, Independent Director | ||
| Ludovic Helfgott, Executive Vice President of Biopharm | ||
| Camilla Sylvest, Executive Vice President - Commercial Strategy and Corporate Affairs | ||
| Mads Thomsen, Chief Science Officer, Executive VP and Member of Executive Management | ||
| Andreas Fibig, Independent Director | ||
| Monique Carter, Executive Vice President - People and Organisation | ||
| Laurence Debroux, Independent Director | ||
| Marcus Schindler, Executive Vice President - Research and Early Development, Chief Scientific Officer | ||
| Stig Stroebaek, Director, Employee Representative | ||
| Henrik Wulff, Executive Vice President - Product Supply Quality and IT |
Novo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novo Nordisk a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.0 | ||||
| Return On Asset | 0.25 | ||||
| Profit Margin | 0.37 % | ||||
| Operating Margin | 0.49 % | ||||
| Current Valuation | 566.38 B | ||||
| Shares Outstanding | 4.46 B | ||||
| Shares Owned By Institutions | 9.27 % | ||||
| Number Of Shares Shorted | 3.24 M | ||||
| Price To Earning | 37.42 X | ||||
| Price To Book | 36.21 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.294 | Earnings Share 2.87 | Revenue Per Share 54.605 | Quarterly Revenue Growth 0.225 | Return On Assets 0.2524 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.